Fact-checked by Grok 2 weeks ago

Abcam

Abcam is a global company specializing in the and supply of high-quality biological reagents and tools, including antibodies, proteins, assays, and kits, to support advancements in , diagnostics, and basic life . Founded in 1998 by Jonathan Milner, a at the , along with collaborators Tony Kouzarides and David Cleevely, Abcam originated as an to simplify access to antibodies for frustrated by unreliable suppliers and inconsistent product quality. Headquartered in , , the company initially operated from a university lab and rapidly expanded by prioritizing rigorous validation, customer feedback, and a broad catalog of products sourced from in-house manufacturing and over 400 partners. By 2023, Abcam had grown into a leading provider, offering more than 110,000 products and serving approximately two-thirds of the world's life scientists across over 130 countries, with a exceeding 1,100 employees at eleven sites. In December of that year, , a -based conglomerate in life sciences and diagnostics, completed its acquisition of Abcam for $5.7 billion at $24 per share, enhancing Danaher's portfolio in protein research tools and accelerating innovations in complex disease mapping and therapeutic development. Under Danaher's ownership as of 2025, Abcam continues to emphasize data-driven antibody development, R&D collaborations, and expert support to empower researchers worldwide.

Company Overview

Products and Services

Abcam specializes in providing high-quality biological reagents and tools for life science , with a primary focus on protein analysis and cellular studies. Their product portfolio encompasses antibodies, proteins, assay kits, and cellular resources, designed to support applications such as Western blotting, , , and . These offerings are complemented by data-driven validation, expert technical support, and rapid global delivery to facilitate reproducible research outcomes. The company's portfolio is extensive, including over 60,000 primary antibodies, along with secondary antibodies and conjugated antibodies, as part of a total catalog exceeding 118,000 validated products. Primary antibodies, available in monoclonal, polyclonal, recombinant, and precision-engineered formats, target diverse antigens to enable precise detection in various experimental protocols; for instance, precision antibodies are optimized for enhanced specificity and lot-to-lot consistency in high-throughput assays. Conjugated variants incorporate fluorophores or enzymes for direct use in imaging and multiplexing applications, with custom conjugation services available to tailor labels to specific research needs. Beyond antibodies, Abcam supplies proteins and peptides, including recombinant forms expressed in bacterial, mammalian, and insect systems, suitable for functional studies, binding assays, and . These are offered in purified formats with accompanying biochemical data to ensure compatibility with downstream applications. Assay kits form another core category, encompassing kits for analyte quantification, biochemical assays for enzyme activity, and cellular assays for , viability, and ; matched antibody pair kits allow researchers to develop customized s in 96- or 384-well formats for scalable screening. Abcam also provides cell lines and lysates, featuring CRISPR-Cas9 gene-edited models that precisely knock out or modify target for studying and signaling pathways. Accessory reagents, such as controls, buffers, and purification tools, support optimization, while multiplex kits enable simultaneous detection of multiple biomarkers in complex samples. In addition to off-the-shelf products, Abcam offers custom services, including antibody development and characterization, where in-house experts generate antibodies against challenging targets with defined specifications for affinity, specificity, and application performance. These services integrate with broader tools like panels and imaging resources to address specialized research demands in areas such as , , and .

Operations and Global Reach

Abcam's operations center on the , , and of high-quality protein research tools, including antibodies, assays, proteins, and kits, designed to support life scientists in accelerating discoveries in , diagnostics, and . The company employs a data-driven approach to validation and , leveraging proprietary technologies and collaborations with over 400 to ensure product reliability and . Manufacturing occurs in specialized facilities worldwide, with an emphasis on and scalability to meet demand from academic, pharmaceutical, and sectors. Following its acquisition by in December 2023, Abcam continues to function as a standalone operating and within Danaher's Life Sciences segment, preserving its operational independence while benefiting from enhanced resources for R&D and market expansion. This structure allows Abcam to maintain its focus on customer-centric operations, including an platform that facilitates direct access to over 118,000 products and global scientific support services. In terms of global reach, Abcam serves approximately 750,000 researchers across more than 130 countries, providing tools to roughly two-thirds of the world's life scientists. The company maintains over 1,100 employees distributed across 11 sites worldwide, enabling localized support, rapid delivery, and regulatory compliance in key markets such as , , and . Through a network of direct offices, laboratories, and distributors, Abcam ensures efficient operations and fosters partnerships that extend its impact in areas like , , and infectious diseases.

History

Founding and Early Years

Abcam was founded in 1998 in , , by Jonathan Milner, David Cleevely, and Tony Kouzarides, a group of scientists frustrated by the inconsistent availability and quality of research-grade antibodies for life sciences experiments. The company emerged from the research ecosystem, with Milner, a genetic researcher, identifying a market gap for a centralized, online platform to streamline access to these essential reagents. Incorporated under the Companies Act, Abcam began operations from the , focusing initially on antibodies sourced from academic labs and manufacturers to support in areas like and protein analysis. In its early years, Abcam prioritized an model to connect directly with suppliers, bypassing traditional distribution challenges and enabling rapid global shipping to over 130 countries. This approach facilitated quick expansion of its product catalog, growing from a niche supplier to offering thousands of validated by the mid-2000s, which helped build trust through rigorous quality controls and customer feedback integration. The company's revenue surged from modest beginnings, reflecting the demand for reliable tools in academic and biotech labs, with early emphasis on digital accessibility setting it apart in the fragmented market. A pivotal milestone came in 2005 when Abcam listed on the () of the London Stock Exchange, providing capital for further scaling while retaining its scientist-led ethos under Milner's CEO leadership. This public debut marked the transition from startup to established player, with initial post-IPO efforts focused on enhancing online search tools and expanding non-antibody products like assays and kits to meet evolving research needs.

Growth and Public Listing

Abcam experienced significant in its early years, driven by the expansion of its online catalog of research antibodies and reagents, which addressed a key need in the life sciences community for accessible, high-quality tools. By 2005, the company's revenue had reached approximately £12 million, nearly double the previous year's figure, fueled by increasing demand from academic and commercial researchers worldwide. This rapid scaling, from a startup founded in 1998 to a revenue-generating entity with a growing international customer base, positioned Abcam for public listing. On November 3, 2005, Abcam completed its (IPO) on the (AIM) of the London under the ticker ABC, raising net proceeds of £9.3 million at an offer price of 167 pence per share, valuing the company at £57.5 million. Following the AIM listing, Abcam sustained strong revenue growth, averaging around 14% annually over the subsequent decade, as it broadened its product portfolio to over 110,000 items and established a global e-commerce platform serving customers in more than 130 countries. Revenue climbed from £83 million in fiscal year 2011 to £260 million in fiscal year 2019, with notable accelerations such as 24.5% growth in 2013, supported by strategic investments in manufacturing, distribution networks in North America and Asia, and selective acquisitions to enhance its catalog. The company remained flat at £260 million in fiscal year 2020 due to COVID-19 disruptions (note that in 2021, Abcam changed its fiscal year end to December 31), but rebounded, achieving £362 million in revenue for the year ended December 31, 2022, reflecting 10-15% constant currency growth rates in recent years through innovation in validated antibodies and biomarkers. To access deeper U.S. capital markets and increase liquidity for its growing American operations, Abcam pursued a secondary listing on the Global Select Market. On October 22, 2020, it priced an offering of 8.9 million American Depositary Shares (ADSs) at $17.50 each, raising approximately $157 million in gross proceeds, with the shares beginning trading under the symbol ABCM on October 22, 2020. This move complemented its listing and supported further expansion, though Abcam later delisted from on December 13, 2022, to streamline its structure while retaining the presence, amid continued revenue guidance of 15-20% growth for fiscal 2023.

Acquisitions

Pre-2023 Acquisitions

Abcam pursued an aggressive acquisition strategy in the years leading up to 2023 to broaden its portfolio of antibodies, assays, and related life sciences tools, focusing on complementary technologies in , custom services, and gene editing. These moves enabled the company to enhance its offerings in high-growth areas such as recombinant antibodies and multiplex analysis, integrating acquired assets to support research in , , and metabolic disorders. By 2022, acquisitions had contributed significantly to revenue diversification, with integrated products accounting for a substantial portion of sales growth. In 2011, Abcam initiated this expansion with the acquisition of MitoSciences, a U.S.-based provider of mitochondrial research tools including antibodies and assays, for $6 million in cash and shares; this deal strengthened Abcam's capabilities in cellular energy pathway studies. Later that year, the company acquired Ascent Scientific, a U.K. specialist in biochemical reagents, for approximately £10 million, adding over 1,000 compounds to its catalog and bolstering its position in and research. The 2012 purchase of Epitomics marked a pivotal expansion into monoclonal antibodies (RabMAbs), with Abcam acquiring the California-based firm for $155 million in cash and stock; Epitomics' proprietary technology improved specificity and performance, leading to the integration of over 1,000 RabMAb products that enhanced Abcam's competitive edge in and applications. This acquisition was particularly impactful, contributing to sustained revenue growth in premium segments. By 2015, Abcam targeted advanced analytics and with two key deals. The acquisition of BioWorks, a Canadian developer of nanoparticle-based multiplex assays, for £18.5 million, introduced the FirePlex platform for and detection, expanding Abcam's tools for high-throughput immune profiling. In November, Abcam acquired AxioMx, a U.S. innovator in proximity assays, for an upfront payment of $18 million plus up to $27 million in milestones; this added the Pan-RabMAb screening technology, enabling faster custom development and supporting applications in and . The year represented a in activity, with multiple acquisitions diversifying into services and gene editing. In , Abcam acquired Biolabs, a firm specializing in recombinant rabbit monoclonal antibodies, for an undisclosed sum, enhancing antibody production for challenging targets in cancer and research. July saw the purchase of EdiGene's live cell line and lysate portfolio, a gene-editing specialist, for undisclosed terms, providing CRISPR-edited models for studies. In November, the company agreed to acquire Expedeon's and business—including Innova Biosciences and TGR BioSciences—for €120 million, adding conjugation technologies and kits; the deal closed in 2020, integrating over 2,000 products to advance protein labeling and detection capabilities. These moves collectively expanded Abcam's addressable market in emerging biotech tools, driving double-digit growth in and revenues. In January 2020, Abcam acquired Applied StemCell's gene-edited cell lines and products, further bolstering its iPSC-derived models for disease modeling. In , Abcam's largest pre-2023 deal was the $340 million acquisition of BioVision, announced in August and completed in , which added over 3,000 kits and recombinant proteins to its portfolio, significantly scaling capabilities in , , and research. This transaction, funded partly through debt, underscored Abcam's focus on high-margin, off-the-shelf consumables and positioned it as a leader in ready-to-use biochemical tools for academic and pharma labs.

Acquisition by Danaher Corporation

On August 28, 2023, announced its agreement to acquire Abcam plc for $24.00 per share in , representing an enterprise value of approximately $5.7 billion. The deal was structured as a , with funding the purchase using available on hand, and was expected to close in mid-2024 subject to customary closing conditions, including regulatory approvals and shareholder consent. Strategically, the acquisition aimed to bolster 's life sciences portfolio by integrating Abcam's expertise in protein research tools, such as antibodies, reagents, and assays, to accelerate advancements in and diagnostics. The transaction faced initial opposition from Abcam's founder and largest individual shareholder, Jonathan Milner, who held approximately 6.14% of the company's shares. In September 2023, Milner publicly stated his intention to vote against the deal, arguing that the $24 per share offer undervalued Abcam and that he had received feedback from other shareholders and analysts supporting a higher valuation. He also called for a general meeting to replace the board, accusing it of underperformance, though Abcam's board described his actions as an attempt to create confusion among investors. Despite this resistance, Milner suspended his "Vote Against" campaign on November 1, 2023, following extensive discussions with shareholders who indicated strong support for the transaction. Abcam shareholders ultimately approved the acquisition on , 2023, with the deal receiving necessary regulatory clearances shortly thereafter. The transaction closed earlier than anticipated on December 6, 2023, marking the successful completion of Danaher's purchase and Abcam's delisting from the Nasdaq and . Post-closure, Abcam began operating as a wholly owned within Danaher's segment, enabling expanded access to resources for innovation in research consumables.

Post-Acquisition Developments

Integration into Danaher

Following the completion of its acquisition by on December 6, 2023, for approximately $5.7 billion, Abcam was integrated into Danaher's Life Sciences segment while maintaining its status as a standalone operating company and brand. This structure allowed Abcam to continue its core operations in providing antibodies, reagents, and other research tools to support scientific discovery in areas such as cancer, neurological disorders, and infectious diseases, serving over 750,000 researchers across more than 130 countries. The integration emphasized leveraging Danaher's Danaher Business System (DBS) for operational efficiencies, including and shared resources across the Life Sciences portfolio, without disrupting Abcam's established R&D and customer-facing activities. Danaher anticipated annual cost synergies of $75 million after five years, primarily from procurement savings, manufacturing improvements, and administrative overlaps, while projecting Abcam to contribute around $550 million in for 2024. In practice, Abcam's performance in 2024 aligned with these expectations, forming part of a combined ~$1 billion contribution from recent acquisitions like Aldevron and Abcam within the sub-segment, which totaled ~$6.8 billion overall. By 2025, Abcam's integration had progressed through routine financial adjustments, such as fair value inventory write-downs impacting early post-acquisition earnings, but the company reported core revenue declines in line with full-year expectations of a low-single digit decline within Danaher's Life Sciences operations. No major structural changes or leadership shifts specific to integration were publicly detailed, reinforcing Abcam's role as an independent entity focused on innovation in protein research tools, with ongoing support from Danaher's global infrastructure to accelerate product development and market reach.

Recent Leadership Changes

Following the completion of its acquisition by on December 6, 2023, Abcam experienced key leadership transitions in early 2024 as part of its integration into the Danaher Life Sciences portfolio. These changes aimed to infuse Danaher's operational expertise and customer-focused strategies into Abcam's structure while maintaining continuity in scientific innovation. On February 26, 2024, Markus Lusser was appointed President of Abcam, replacing Alan Hirzel, who had served as CEO since September 2014 and led the company's expansion, tripling revenues during his tenure through global growth and product diversification. Lusser, a Danaher veteran since 2007 with prior roles including , was selected to prioritize customer needs, foster collaboration across Danaher's ecosystem, and accelerate Abcam's innovation in and reagent development. The transition marked a shift toward deeper alignment with Danaher's (Danaher Business System) principles for efficiency and scalability. Alongside Lusser's appointment, Abcam named Knud Müller as in early 2024. Müller, who joined from Danaher where he held senior finance positions in the and for over 15 years, was tasked with overseeing financial operations, , and integration efforts to support Abcam's post-acquisition growth in the life sciences market. His background in managing finances for Danaher's diagnostics and life sciences businesses positions him to enhance Abcam's fiscal discipline amid expanding global operations. Other senior roles saw continuity with strategic emphases. Alejandra Solache continued as Senior Vice President of Research & Development, a position she has held since December 2013, directing to tackle reproducibility challenges in life sciences through recombinant antibodies and validation protocols. The broader executive team, including Nadia Altomare as of Commercial Operations and Ahmed Hasan as , supports these priorities by optimizing sales, , and digital tools for researchers. As of November 2025, Abcam's leadership has remained stable under Lusser's presidency, with no further major executive changes announced, allowing focus on leveraging Danaher synergies for enhanced R&D output and market expansion. This stability reflects successful post-acquisition , as evidenced by Abcam's recognition in industry awards for innovation in .

References

  1. [1]
    About | Abcam
    ### Summary of Abcam
  2. [2]
    Abcam | Danaher
    Founded in 1998 and headquartered in Cambridge, UK, abcam started with a simple mission: to provide the best biological reagents to life scientists worldwide.
  3. [3]
    https://www.abcam.com/en-us/press-releases/open-for-business
  4. [4]
    Deck Review with Abcam - by Joshua Elkington - Axial
    Mar 13, 2022 · Abcam was founded in 1998 by Jonathan Milner, Tony Kouzarides, and David Cleevely to build a marketplace for antibodies. Milner was a ...Missing: history | Show results with:history
  5. [5]
    Abcam | Company Overview & News - Forbes
    Abcam Plc distributes antibodies and associated protein research tools. Its product range includes primary and secondary antibodies, proteins, peptides,
  6. [6]
    Danaher Completes Acquisition of Abcam - Dec 6, 2023
    Dec 6, 2023 · The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies ...
  7. [7]
    Danaher completes $5.7 billion acquisition of Abcam | Reuters
    Dec 6, 2023 · Danaher agreed to buy Abcam in September for $24 per share to expand its portfolio of products and services, but founder Jonathan Milner opposed ...
  8. [8]
    Danaher to Acquire Abcam - Aug 28, 2023
    Aug 28, 2023 · A global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Abcam plc (NASDAQ: ABCM).
  9. [9]
    https://www.abcam.com/en-us/products/primary-antibodies
  10. [10]
    https://www.abcam.com/en-us/technical-resources/product-overview/conjugated-antibodies
  11. [11]
    https://www.abcam.com/index.html
  12. [12]
    https://www.abcam.com/en-us/products/proteins-peptides
  13. [13]
    https://www.abcam.com/en-us/products/elisa-kits
  14. [14]
    https://www.abcam.com/nav/elisa-and-matched-antibody-pair-kits/matched-antibody-pair-kits-and-reagents
  15. [15]
    https://www.abcam.com/en-us/products/cell-lines
  16. [16]
    None
    Nothing is retrieved...<|control11|><|separator|>
  17. [17]
    https://www.abcam.com/en-us/products/product-recommendations/custom-antibody-development-and-characterization-services
  18. [18]
    https://www.abcam.com/en-us/products/product-recommendations
  19. [19]
    [PDF] Abcam plc - AnnualReports.com
    Abcam was established in 1998 as a global web-based antibody company providing high-quality reagents. Today, we're more than just antibodies. We've added ...
  20. [20]
    The Rise of Abcam: A Small-Cap Multi-Bagger - Stockopedia
    Abcam was founded in 1998 by a group of researchers at Cambridge University who sought easy access to high quality antibodies. It was a time when successful ...
  21. [21]
    Abcam - the Next Giant of the Life Sciences? - Business Insider
    May 3, 2011 · Abcam (LON:ABC) was founded in a Cambridge research lab in 1998 with the simple idea of making it easier for research scientists to buy antibodies across the ...
  22. [22]
    StockWatch: Abcam, Founder Spar over Company's Future
    Jun 23, 2023 · Milner founded Abcam in 1998, oversaw its going public in 2005, and served as CEO through 2014, when he was succeeded by Hirzel, then the ...
  23. [23]
    [PDF] Annual report and accounts
    Sep 4, 2006 · No options over ordinary shares have been granted since the. IPO in November 2005. It is the intention to grant additional options on a regular ...<|control11|><|separator|>
  24. [24]
    Investors back Abcam delisting plan - The Times
    Sep 13, 2022 · The group joined the Aim market in November 2005, when it was valued at £57.5 million. It is now one of the country's biggest biotech companies ...<|control11|><|separator|>
  25. [25]
    Financial Statements for Abcam plc (ABCZY) - QuickFS.net
    2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020. Revenue, 135, 152, 189, 217, 224, 244, 278, 310, 329, 325. Revenue Growth, 28.5%, 12.7%, 24.5% ...
  26. [26]
    Revenue - Abcam PLC (OTC:ABCZF) - Alpha Spread
    Over the last year, the Revenue growth was 18%. The average annual Revenue growth rates for Abcam PLC have been 10% over the past three years , 10% over the ...
  27. [27]
    Abcam - Wikipedia
    Abcam Limited is a producer, distributor and seller of protein research tools operating worldwide from 13 locations with 1,800 employees of which 400 work ...
  28. [28]
    UK-based research tool provider Abcam prices US IPO at $17.50
    Oct 22, 2020 · Abcam, which sells biological reagents and tools for research, drug discovery, and diagnostics, raised $157 million by offering 8.9 million ADSs at $17.50.Missing: date | Show results with:date
  29. [29]
    Abcam Announces Pricing of Offering on NASDAQ - GlobeNewswire
    Oct 22, 2020 · The closing of the Offering is expected to occur on October 26, 2020, subject to customary closing conditions. Abcam's ordinary shares are ...
  30. [30]
    https://www.abcam.com/en-us/press-releases/proposed-cancellation-of-admission-of-ordinary-shares-to-trading-on-aim
  31. [31]
    https://www.abcam.com/en-us/press-releases/abcam-to-acquire-biovision-for-340-million
  32. [32]
    https://www.abcam.com/en-us/press-releases/abcam-acquires-mitosciences-in-deal-which-enhances-immunoassay-portfolio
  33. [33]
    https://www.abcam.com/en-us/press-releases/abcam-acquires-ascent-scientific-a-specialist-provider-of-biochemicals
  34. [34]
    Acquisitions boost Abcam full-year profit - Reuters
    Sep 10, 2013 · Abcam acquired U.S. peer Epitomics for $155 million in March 2012 and took over the development and distribution of rabbit monoclonal antibodies ...
  35. [35]
    https://www.abcam.com/en-us/press-releases/rabbit-monoclonal-antibodies-available-from-abcam-following-acquisition-of-epitomics
  36. [36]
    https://www.abcam.com/en-us/press-releases/abcam-acquires-axiomx
  37. [37]
    Abcam to Acquire AxioMx for Up to $45M
    Nov 11, 2015 · Abcam said today it will acquire AxioMx for up to $45 million, in a deal intended to enable the buyer to expand its offerings to customers ...
  38. [38]
    Abcam plc Acquires Firefly BioWorks To Expand Capabilities In ...
    Jan 21, 2015 · Abcam plc Acquires Firefly BioWorks To Expand Capabilities In Multiplex Analysis. January 21, 2015 |. 5 min read.
  39. [39]
    https://www.abcam.com/en-us/press-releases/abcam-expands-custom-services-capabilities-with-the-acquisition-of-calico-biolabs
  40. [40]
    Abcam acquires EdiGene's cell lines and lysates portfolio
    Jul 16, 2019 · Abcam has entered the cell editing market through acquisition of the entire live cell line and lysates portfolio of EdiGene Inc.
  41. [41]
    Abcam Genetics & Genomics News | GenomeWeb
    Abcam Acquires Applied StemCell Gene Editing Platform, Oncology Product Line. Nov 11, 2019. Expedeon to Sell Proteomics, Immunology Businesses to Abcam for $130 ...
  42. [42]
    https://www.abcam.com/en-us/press-releases/abcam-agrees-to-acquire-expedeons-proteomics-and-immunology-business
  43. [43]
    Expedeon AG and Abcam plc close EUR 120 million transaction
    Jan 5, 2020 · The closing triggers a payment of EUR 120 million by Abcam to Expedeon, of which EUR 105.6 million is due immediately and EUR 14.4 million will ...Missing: acquires date
  44. [44]
    https://www.abcam.com/en-us/press-releases/abcam-completes-strategic-acquisition-and-expands-kit-capacity-and-capability
  45. [45]
    Danaher to Acquire Abcam - PR Newswire
    Aug 28, 2023 · Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash, or a total enterprise value of approximately $5.7 billion.
  46. [46]
    Danaher buying reagent firm Abcam for $5.7bn - BioProcess Insider
    Aug 28, 2023 · Danaher Corporation will add antibodies, reagents, biomarkers, and assays to its life sciences offering through the acquisition of Abcam.
  47. [47]
    Abcam founder seeks to block $5.7 billion Danaher deal - Reuters
    Sep 14, 2023 · Abcam considers it "surprising" that Milner is taking steps to oppose the deal which appears to be an attempt to create confusion for ...
  48. [48]
    StockWatch: Abcam Founder Opposes $5.7B Danaher Acquisition
    Sep 17, 2023 · In a statement, Milner said he decided to oppose the Danaher buyout based on “extensive feedback received from many shareholders and analysts, ...
  49. [49]
    Statement from Dr. Jonathan Milner on the suspension of the “Vote ...
    Nov 1, 2023 · “After extensive feedback from the majority of Abcam's shareholders, I have today decided to suspend my “Vote AGAINST” campaign. It has become ...Missing: opposition | Show results with:opposition
  50. [50]
    Press Releases - Danaher | Investor Overview
    Standard. Basic Search. Download PDF. Danaher Completes Acquisition of Abcam. Dec 6, 2023. Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has ...
  51. [51]
    Danaher Completes $5.7B Acquisition of Abcam | Contract Pharma
    Dec 6, 2023 · Danaher Completes $5.7B Acquisition of Abcam. Abcam is a supplier of protein research tools for life sciences based in Cambridge, England.
  52. [52]
    Danaher to buy antibody supplier Abcam for $5.7B - MedTech Dive
    Aug 28, 2023 · Abcam is expected to report 2024 revenues of $550 million, and the companies anticipate annual synergies of $75 million after five years, the ...Missing: integration progress
  53. [53]
    [PDF] 2024 Overview - Danaher Corporation
    All financial metrics reflect FY 2024 results from continuing operations; all pie chart percentages are % of 2024 revenues.
  54. [54]
    Danaher Reports Second Quarter 2025 Results
    Jul 22, 2025 · Costs incurred for the fair value adjustment to inventory related to the acquisition of Abcam plc for the six-month period ended June 28, 2024 ...
  55. [55]
    Danaher Reports Third Quarter 2025 Results
    Oct 21, 2025 · 21, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 26, 2025. Key ...
  56. [56]
    https://www.abcam.com/en-us/press-releases/abcam-appoints-markus-lusser-as-new-president
  57. [57]
    Abcam appoints Markus Lusser as new President - PR Newswire
    Mar 18, 2024 · A seasoned Danaher executive, Markus joins Abcam at a pivotal moment as the company transitions into the Danaher Life Sciences portfolio. His ...
  58. [58]
    New broom at the top: Lusser in, Hirzel out as Danaher triggers new ...
    Mar 17, 2024 · Markus Lusser becomes President at the life science research tools supplier – replacing Alan Hirzel who was CEO since 2014 and previously headed marketing at ...
  59. [59]
    https://www.abcam.com/en-us/about/our-people/knud-muller
  60. [60]
    https://www.abcam.com/en-us/about/our-people/alejandra-solache
  61. [61]
    Our people | Abcam
    ### Leadership Team Summary
  62. [62]
    https://www.abcam.com/en-us/press-releases/abcam-wins-antibody-supplier-succeeding-in-genetics-research-citeab-award-2025